<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="es"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Hepatol</journal-id><journal-title-group><journal-title>Gastroenterologia Y Hepatologia</journal-title></journal-title-group><issn pub-type="ppub">0210-5705</issn><issn pub-type="epub">0210-5705</issn><publisher><publisher-name>Elsevier Espa&#x000f1;a, S.L.U.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7290227</article-id><article-id pub-id-type="pii">S0210-5705(20)30215-6</article-id><article-id pub-id-type="doi">10.1016/j.gastrohep.2020.06.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Revisi&#x000f3;n</subject></subj-group></article-categories><title-group><article-title>Inmunosupresi&#x000f3;n en el trasplante hep&#x000e1;tico en la era covid-19</article-title><trans-title-group xml:lang="en"><trans-title>Liver transplant immunosuppression during the covid-19 pandemic</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Forns</surname><given-names>Xavier</given-names></name></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Navasa</surname><given-names>Miquel</given-names></name><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff0005">Unidad de Hepatitis V&#x000ed;ricas y Unidad de Trasplante Hep&#x000e1;tico, Servicio de Hepatolog&#x000ed;a, Hospital Cl&#x000ed;nic. Universitat de Barcelona, IDIBAPS, CIBERehd, Barcelona, Espa&#x000f1;a</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Autor para correspondencia.</corresp></author-notes><pub-date pub-type="pmc-release"><day>12</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>10</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2020</year></pub-date><volume>43</volume><issue>8</issue><fpage>457</fpage><lpage>463</lpage><history><date date-type="received"><day>13</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>7</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Espa&#x000f1;a, S.L.U. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Espa&#x000f1;a, S.L.U.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>La infecci&#x000f3;n por el virus SARS-CoV-2 ha producido una pandemia con graves consecuencias sobre nuestro sistema sanitario. Aunque el colectivo de pacientes trasplantados hep&#x000e1;ticos representa solo una minor&#x000ed;a de la poblaci&#x000f3;n, los hepat&#x000f3;logos que seguimos a estos pacientes hemos intentado coordinar esfuerzos para protocolizar el manejo de la inmunosupresi&#x000f3;n durante la infecci&#x000f3;n por SARS-CoV-2. Aunque no hay estudios s&#x000f3;lidos que avalen recomendaciones generales, las experiencias con otras infecciones v&#x000ed;ricas (hepatitis C, citomegalovirus) sugieren que el manejo de la inmunosupresi&#x000f3;n sin micofenolato mofetilo ni inhibidores m-Tor (f&#x000e1;rmacos que adem&#x000e1;s se asocian a leucopenia y linfopenia) puede resultar beneficiosa. Es importante adem&#x000e1;s prestar atenci&#x000f3;n a las posibles interacciones farmacol&#x000f3;gicas, especialmente en el caso de tacrolimus, con algunos de los tratamientos con efecto antiviral que se administran en el contexto de la covid-19 (lopinavir/ritonavir, azitromicina). Finalmente, deber&#x000e1; tenerse en cuenta el efecto inmunosupresor de f&#x000e1;rmacos inmunomoduladores (tocilizumab y similares) que se administran en pacientes con enfermedad pulmonar severa. En el art&#x000ed;culo se revisan los mecanismos de actuaci&#x000f3;n de los diferentes f&#x000e1;rmacos inmunosupresores, su potencial efecto sobre la infecci&#x000f3;n por SARS-CoV-2 y se sugieren unas pautas en el manejo de la inmunosupresi&#x000f3;n.</p></abstract><trans-abstract xml:lang="en"><p>SARS-CoV-2 infection has produced a pandemic with serious consequences for our health care system. Although liver transplant patients represent only a minority of the population, the hepatologists who follow these patients have tried to coordinate efforts to produce a protocol the management of immunosuppression during SARS-CoV-2 infection. Although there are no solid studies to support general recommendations, experiences with other viral infections (hepatitis C, cytomegalovirus) suggest that management of immunosuppression without mycophenolate mofetil or m-Tor inhibitors (drugs that are also associated with leukopenia and lymphopenia) may be beneficial. It is also important to pay attention to possible drug interactions, especially in the case of tacrolimus, with some of the treatments with antiviral effect given in the context of COVID 19 (lopinavir/ritonavir, azithromycin). Finally, the immunosuppressive effect of immunomodulating drugs (tocilizumab and similar) administered to patients with severe lung disease should be taken into account. The mechanisms of action of the different immunosuppressive drugs are reviewed in this article, as well as their potential effect on SARS-CoV-2 infection, and suggests guidelines for the management of immunosuppression.</p></trans-abstract><kwd-group id="kwd0005"><title>Palabras clave</title><kwd>SARS-CoV-2</kwd><kwd>Inmunosupresi&#x000f3;n</kwd><kwd>Inmunomoduladores</kwd><kwd>Citoquinas</kwd><kwd>Neumon&#x000ed;a</kwd><kwd>Trasplante hep&#x000e1;tico</kwd></kwd-group><kwd-group xml:lang="en" id="kwd0010"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>Immunosuppression</kwd><kwd>Immunomodulation</kwd><kwd>Cytokines</kwd><kwd>Pneumonia</kwd><kwd>Liver transplant</kwd></kwd-group></article-meta></front><body><p id="par0005">La infecci&#x000f3;n por el virus SARS-CoV-2 ha producido una pandemia con graves repercusiones sanitarias y econ&#x000f3;micas. En la lucha por la supervivencia de los pacientes, los m&#x000e9;dicos hemos probado con m&#x000e1;s o menos acierto m&#x000fa;ltiples f&#x000e1;rmacos dirigidos a combatir el virus o sus efectos en el organismo<xref rid="bib0320" ref-type="bibr">1</xref>, <xref rid="bib0325" ref-type="bibr">2</xref>, <xref rid="bib0330" ref-type="bibr">3</xref>, <xref rid="bib0335" ref-type="bibr">4</xref>, <xref rid="bib0340" ref-type="bibr">5</xref>, <xref rid="bib0345" ref-type="bibr">6</xref>, <xref rid="bib0350" ref-type="bibr">7</xref>, <xref rid="bib0355" ref-type="bibr">8</xref>, <xref rid="bib0360" ref-type="bibr">9</xref>, <xref rid="bib0365" ref-type="bibr">10</xref>. Los pacientes trasplantados hep&#x000e1;ticos son una minor&#x000ed;a de la poblaci&#x000f3;n, pero su condici&#x000f3;n de inmunosuprimidos los hace en teor&#x000ed;a m&#x000e1;s sensibles a la infecci&#x000f3;n, por lo que los hepat&#x000f3;logos que nos dedicamos al trasplante hep&#x000e1;tico hemos estado muy pendientes de nuestros pacientes y hemos intentado ajustar la inmunosupresi&#x000f3;n tanto a la gravedad de la enfermedad como a los tratamientos que se han utilizado. En este art&#x000ed;culo se detallan los mecanismos de actuaci&#x000f3;n de cada inmunosupresor, se especifica el balance entre su efecto inmunosupresor y el antiviral en algunos casos, y finalmente se hace una propuesta de actuaci&#x000f3;n en relaci&#x000f3;n con el tratamiento inmunosupresor en pacientes con covid-19.</p><sec id="sec0005"><title>El virus SARS-CoV-2</title><p id="par0010">El virus SARS-CoV-2 es un virus que pertenece a la familia <italic>Coronaviridae</italic>, que incluye 4 g&#x000e9;neros (alfa, beta, gamma y delta). Los coronavirus con capacidad de infectar a humanos pertenecen a los g&#x000e9;neros alfa (HCoV-229E y HCoV-NL63) y beta (SARS-CoV, MERS-CoV, HCoV-OC43 y HCoV-HKU1)<xref rid="bib0370" ref-type="bibr">11</xref>, <xref rid="bib0375" ref-type="bibr">12</xref>. En este &#x000fa;ltimo g&#x000e9;nero se incluyen los 3 agentes que hasta la fecha son conocidos por producir infecciones del tracto respiratorio inferior y que por tanto se pueden asociar a cuadros cl&#x000ed;nicos graves (SARS-CoV, MERS-CoV y SARS-CoV-2). Como otros agentes de su familia, SARS-CoV-2 es un virus RNA de cadena positiva, que codifica en diferentes marcos de lectura abierta u <italic>open reading frames</italic> prote&#x000ed;nas estructurales (nucleoc&#x000e1;pside, membrana, envuelta y espiga o &#x000ab;S&#x000bb;) y no estructurales (RNA polimerasa, proteasas)<xref rid="bib0380" ref-type="bibr">13</xref>, <xref rid="bib0385" ref-type="bibr">14</xref>, <xref rid="bib0390" ref-type="bibr">15</xref>. Muy recientemente se ha podido conocer que para su entrada en las c&#x000e9;lulas del organismo el virus utiliza los receptores ACE 2 y posiblemente otros receptores adicionales (como ocurre con muchos otros virus)<xref rid="bib0395" ref-type="bibr">16</xref>, <xref rid="bib0400" ref-type="bibr">17</xref>, <xref rid="bib0405" ref-type="bibr">18</xref>, <xref rid="bib0410" ref-type="bibr">19</xref>.</p><p id="par0015">SARS-CoV-2 tiene como fuente primaria de contagio la transmisi&#x000f3;n entre personas a trav&#x000e9;s de contacto estrecho o a partir de los f&#x000f3;mites cuando un paciente tose. Tiene una elevada infectividad, principalmente durante las primeras fases, colonizando el organismo a trav&#x000e9;s del tracto respiratorio y en especial infectando a las c&#x000e9;lulas epiteliales alveolares<xref rid="bib0410" ref-type="bibr">19</xref>, <xref rid="bib0415" ref-type="bibr">20</xref>. Su replicaci&#x000f3;n es r&#x000e1;pida y se generaliza la infecci&#x000f3;n, que en la mayor&#x000ed;a de los casos (80%) es asintom&#x000e1;tica o leve<xref rid="bib0385" ref-type="bibr"><sup>14</sup></xref>. Se distinguen tres fases: una primera fase asintom&#x000e1;tica con una elevada carga viral; una segunda fase sintom&#x000e1;tica leve, con tos seca, odinofagia, anosmia, fiebre, cansancio y en ocasiones diarrea; y la tercera fase, que caracteriza a los casos graves, produce neumon&#x000ed;a con insuficiencia respiratoria y disnea, puede conducir al s&#x000ed;ndrome de distr&#x000e9;s respiratorio del adulto y finalmente a fallo multiorg&#x000e1;nico y muerte<xref rid="bib0385" ref-type="bibr">14</xref>, <xref rid="bib0405" ref-type="bibr">18</xref>, <xref rid="bib0415" ref-type="bibr">20</xref>. En esta tercera fase la viremia puede ser baja y la afectaci&#x000f3;n tanto pulmonar como endotelial, mioc&#x000e1;rdica, etc., se debe a la denominada tormenta citoqu&#x000ed;nica, que resultar&#x000ed;a de la respuesta exagerada del sistema inmune a la infecci&#x000f3;n por el SARS-CoV-2<xref rid="bib0420" ref-type="bibr"><sup>21</sup></xref>. La enfermedad cl&#x000ed;nica correspondiente a esta infecci&#x000f3;n v&#x000ed;rica es lo que conocemos como covid-19.</p></sec><sec id="sec0010"><title>El sistema inmune en la respuesta ante el SARS-CoV-2</title><sec id="sec0015"><title>Respuesta innata</title><p id="par0020">La presencia de linfopenia con neutrofilia, niveles elevados de IL-6, incremento de la prote&#x000ed;na C reactiva, as&#x000ed; como el hallazgo de niveles elevados de citoquinas asociadas a la inmunidad innata como IP-10, MCP-1, MIP-1&#x003b1; y TNF&#x003b1; sugieren que esta juega un papel muy importante en la respuesta inflamatoria asociada a la infecci&#x000f3;n (que tambi&#x000e9;n se observ&#x000f3; con el SARS-CoV y MERS-CoV) y por tanto, que sea responsable de la evoluci&#x000f3;n hacia la gravedad de covid-19<xref rid="bib0420" ref-type="bibr">21</xref>, <xref rid="bib0425" ref-type="bibr">22</xref>, <xref rid="bib0430" ref-type="bibr">23</xref>, <xref rid="bib0435" ref-type="bibr">24</xref>, <xref rid="bib0440" ref-type="bibr">25</xref>.</p><p id="par0025">La respuesta efectora inmune innata contra los virus se basa mayoritariamente en el interfer&#x000f3;n (IFN-1)<xref rid="bib0430" ref-type="bibr"><sup>23</sup></xref>. Para ello, las c&#x000e9;lulas de la respuesta inmune innata deben reconocer la invasi&#x000f3;n del virus a trav&#x000e9;s de los patrones moleculares asociados a pat&#x000f3;genos (PAMPs)<xref rid="bib0430" ref-type="bibr"><sup>23</sup></xref>. Este reconocimiento conduce a la activaci&#x000f3;n de IFN-1 y otras citoquinas proinflamatorias<xref rid="bib0435" ref-type="bibr">24</xref>, <xref rid="bib0440" ref-type="bibr">25</xref>. Sin embargo, tal y como ocurre con otras infecciones virales, SARS-CoV y MERS-CoV contienen algunas prote&#x000ed;nas que antagonizan v&#x000ed;as de se&#x000f1;alizaci&#x000f3;n cruciales para la activaci&#x000f3;n del interfer&#x000f3;n, como la asociada al reconocimiento de los PAMPs<xref rid="bib0430" ref-type="bibr"><sup>23</sup></xref>. El bloqueo de las v&#x000ed;as de interfer&#x000f3;n facilitar&#x000ed;a la replicaci&#x000f3;n del virus y la liberaci&#x000f3;n de m&#x000e1;s citoquinas proinflamatorias que inducir&#x000ed;an una respuesta excesiva. Una inhibici&#x000f3;n similar parece ocurrir durante la covid-19<xref rid="bib0445" ref-type="bibr"><sup>26</sup></xref>.</p></sec><sec id="sec0020"><title>Respuesta adaptativa</title><p id="par0030">En general, la respuesta inmune tipo Th&#x000a0;1 tiene un papel predominante en las infecciones virales<xref rid="bib0425" ref-type="bibr">22</xref>, <xref rid="bib0440" ref-type="bibr">25</xref>, <xref rid="bib0450" ref-type="bibr">27</xref>. Las citoquinas generadas por las c&#x000e9;lulas presentadoras de ant&#x000ed;genos dirigen la respuesta de las c&#x000e9;lulas T: las c&#x000e9;lulas T reguladoras en general coordinan la respuesta adaptativa, mientras que las c&#x000e9;lulas T citot&#x000f3;xicas son esenciales para la eliminaci&#x000f3;n del virus. La respuesta inmune humoral juega un papel en la limitaci&#x000f3;n de la infecci&#x000f3;n y la prevenci&#x000f3;n de la reinfecci&#x000f3;n por medio de la producci&#x000f3;n de anticuerpos neutralizantes<xref rid="bib0450" ref-type="bibr">27</xref>, <xref rid="bib0455" ref-type="bibr">28</xref>, <xref rid="bib0460" ref-type="bibr">29</xref>, <xref rid="bib0465" ref-type="bibr">30</xref>, <xref rid="bib0470" ref-type="bibr">31</xref>, <xref rid="bib0475" ref-type="bibr">32</xref>, <xref rid="bib0480" ref-type="bibr">33</xref>.</p></sec></sec><sec id="sec0025"><title>Inmunosupresi&#x000f3;n en el trasplante hep&#x000e1;tico y covid-19</title><p id="par0035">La inmunosupresi&#x000f3;n en el trasplante hep&#x000e1;tico, aunque utilice los mismos f&#x000e1;rmacos que los utilizados en otros trasplantes de &#x000f3;rgano s&#x000f3;lido, se caracteriza por ser de una menor intensidad<xref rid="bib0485" ref-type="bibr">34</xref>, <xref rid="bib0490" ref-type="bibr">35</xref>, <xref rid="bib0495" ref-type="bibr">36</xref>, <xref rid="bib0500" ref-type="bibr">37</xref>. Esta particularidad permite en determinados momentos retirar temporalmente alguno de los inmunosupresores que se est&#x000e9;n utilizando, como es el caso de una infecci&#x000f3;n grave, insuficiencia renal, alteraciones neurol&#x000f3;gicas, etc.<xref rid="bib0485" ref-type="bibr">34</xref>, <xref rid="bib0490" ref-type="bibr">35</xref>. Como hemos visto, la respuesta inmunitaria juega un papel muy importante en la enfermedad covid-19, y por tanto, los inmunosupresores habitualmente utilizados podr&#x000ed;an ser determinantes tanto como favorecedores de la infecci&#x000f3;n como atenuadores de la respuesta inflamatoria secundaria a la misma. Los pocos estudios publicados, algunos m&#x000e1;s que estudios son simples reportes de casos, no sugieren ni un aumento en la incidencia de casos en pacientes trasplantados, ni una mayor mortalidad que en la poblaci&#x000f3;n general<xref rid="bib0505" ref-type="bibr">38</xref>, <xref rid="bib0510" ref-type="bibr">39</xref>. Resultados preliminares del estudio de la Sociedad Espa&#x000f1;ola de Trasplante Hep&#x000e1;tico (SETH) sugieren que la mortalidad se situar&#x000ed;a alrededor del 15% de los pacientes infectados que se recogieron en las unidades de trasplante hep&#x000e1;tico en Espa&#x000f1;a<xref rid="bib0515" ref-type="bibr"><sup>40</sup></xref>. Sin embargo, muchos de los resultados que se presentan en la bibliograf&#x000ed;a tienen el sesgo de no conocer la poblaci&#x000f3;n real de infectados, por lo que las cifras que se proporcionan en relaci&#x000f3;n con la incidencia de la infecci&#x000f3;n, mortalidad, etc., deben contar con esta salvedad. Entre los argumentos que se exponen como razones para una menor incidencia de infectados en la poblaci&#x000f3;n trasplantada se consideran: una mayor higiene personal y lavado de manos habitual, la utilizaci&#x000f3;n m&#x000e1;s habitual de medidas de protecci&#x000f3;n y el ser mucho m&#x000e1;s conscientes de la utilidad del distanciamiento social.</p><p id="par0040">En el trasplante hep&#x000e1;tico, como en el de otros &#x000f3;rganos s&#x000f3;lidos, el tratamiento inmunosupresor se basa en un inhibidor de la calcineurina, ciclosporina o tacrolimus, siendo este &#x000fa;ltimo el m&#x000e1;s utilizado, asociado o no a corticoides. Adem&#x000e1;s, principalmente en casos con insuficiencia renal o con objeto de prevenirla, se utiliza micofenolato mofetilo (MMF) y menos frecuentemente un inhibidor de la m-Tor, como everolimus, para poder disminuir los niveles necesarios de anticalcineur&#x000ed;nico.</p><p id="par0045">En el contexto de una infecci&#x000f3;n covid-19 en un paciente trasplantado hep&#x000e1;tico, es muy importante revisar la pauta inmunosupresora. Requieren una especial atenci&#x000f3;n las potenciales interacciones de los inmunosupresores con f&#x000e1;rmacos antivirales o antibacterianos utilizados en las fases iniciales de la infecci&#x000f3;n por SARS-CoV-2 (lopinavir/ritonavir, azitromicina). As&#x000ed; mismo, debe valorarse tambi&#x000e9;n la interacci&#x000f3;n con otros inmunomoduladores dirigidos directamente a la respuesta citoqu&#x000ed;nica (anti-IL6, anti-IL1), utilizados en el tratamiento de los pacientes graves covid-19<xref rid="bib0445" ref-type="bibr">26</xref>, <xref rid="bib0520" ref-type="bibr">41</xref>, <xref rid="bib0525" ref-type="bibr">42</xref>: inhibidores de la se&#x000f1;al del receptor de interleucina 6 (tocilizumab, sarilumab), del receptor de la interleucina 1 (anakinra), o inhibidores selectivos de la Janus quinasa (JAK)<xref rid="bib0525" ref-type="bibr">42</xref>, <xref rid="bib0530" ref-type="bibr">43</xref>, <xref rid="bib0535" ref-type="bibr">44</xref>. Aunque el efecto que estos &#x000fa;ltimos pueden tener sobre el control del rechazo celular en pacientes trasplantados es poco conocido, s&#x000ed; existen datos que sugieren que pueden controlar el rechazo mediado por anticuerpos<xref rid="bib0540" ref-type="bibr"><sup>45</sup></xref>. En cualquier caso, su administraci&#x000f3;n deber&#x000e1; tenerse en cuenta a la hora de ajustar las dosis de corticoides y evitar as&#x000ed; el riesgo de una excesiva inmunosupresi&#x000f3;n.</p><p id="par0050">A continuaci&#x000f3;n, se exponen los principales efectos inmunol&#x000f3;gicos de los inmunosupresores m&#x000e1;s habituales en el trasplante hep&#x000e1;tico.</p><sec id="sec0030"><title>Glucocorticoides</title><p id="par0055">Los glucocorticoides (GC) inhiben diferentes aspectos de la inflamaci&#x000f3;n al estimular o inhibir la transcripci&#x000f3;n de genes, y la expresi&#x000f3;n de mediadores, receptores, mol&#x000e9;culas de adhesi&#x000f3;n y de citocinas. Es por ello que su efecto es m&#x000fa;ltiple y mientras que por un lado pueden favorecer la replicaci&#x000f3;n viral, son potentes antiinflamatorios que pueden ayudar a contrarrestar la tormenta citoqu&#x000ed;nica de la enfermedad. Los GC pueden controlar la inflamaci&#x000f3;n en el s&#x000ed;ndrome de distr&#x000e9;s respiratorio del adulto (SDRA) y se utilizan en las formas primarias y secundarias de linfohistiocitosis hemofagoc&#x000ed;tica<xref rid="bib0545" ref-type="bibr">46</xref>, <xref rid="bib0550" ref-type="bibr">47</xref>, <xref rid="bib0555" ref-type="bibr">48</xref>. Sin embargo, resultados preliminares de la utilizaci&#x000f3;n de altas dosis de corticoides en SARS y covid-19 no han demostrado un efecto beneficioso sobre la lesi&#x000f3;n pulmonar<xref rid="bib0560" ref-type="bibr"><sup>49</sup></xref>. No obstante, pautas cortas de dosis medias-bajas de GC se demostraron &#x000fa;tiles en un estudio en enfermos cr&#x000ed;ticos covid-19 en China<xref rid="bib0550" ref-type="bibr"><sup>47</sup></xref>. Estos datos tan limitados en cuanto a eficacia y seguridad de los GC, la ausencia de estudios controlados y su asociaci&#x000f3;n con otros tratamientos hacen pr&#x000e1;cticamente imposible extraer conclusiones fiables. La recomendaci&#x000f3;n &#x000fa;ltima es que los bolus de GC en altas dosis no deben usarse en el tratamiento de la covid-19.</p><p id="par0060">Su utilizaci&#x000f3;n en el trasplante hep&#x000e1;tico es variable. Pueden usarse o no durante los 6 primeros meses en asociaci&#x000f3;n con los otros inmunosupresores y se usan en bolus a altas dosis como tratamiento del rechazo celular grave. A partir de este per&#x000ed;odo postrasplante (que puede oscilar entre 0 y 6 meses), los corticoides se retiran a excepci&#x000f3;n de los pacientes que hayan sido trasplantados por patolog&#x000ed;a hep&#x000e1;tica de etiolog&#x000ed;a autoinmune, en los que se suelen mantener dosis bajas de forma muy prolongada. Otro uso de los GC es complementar o substituir la inmunosupresi&#x000f3;n de base durante cortos per&#x000ed;odos de tiempo, cuando se han producido complicaciones graves que obligan a la suspensi&#x000f3;n de la medicaci&#x000f3;n inmunosupresora habitual, como por ejemplo en casos de sepsis grave e insuficiencia renal<xref rid="bib0475" ref-type="bibr"><sup>32</sup></xref>. En funci&#x000f3;n del tiempo transcurrido tras el trasplante se utilizan, por per&#x000ed;odos de entre una y 2 semanas, corticoides a dosis variables que van en la mayor&#x000ed;a de los casos de 20 a 60&#x000a0;mg/d&#x000ed;a.</p><p id="par0065">En caso de enfermedad grave covid-19, la substituci&#x000f3;n temporal de anticalcineur&#x000ed;nicos y MMF por GC permite a estos pacientes evitar efectos indeseables secundarios a la interacci&#x000f3;n de dichos inmunosupresores con los m&#x000fa;ltiples medicamentos que reciben para el tratamiento de la infecci&#x000f3;n por SARS-CoV-2. Adem&#x000e1;s previene de los propios efectos secundarios de los inmunosupresores (insuficiencia renal, agravamiento de la linfopenia, etc.). Aunque se ha indicado que la retirada incontrolada de la inmunosupresi&#x000f3;n puede producir el rechazo del injerto<xref rid="bib0565" ref-type="bibr"><sup>50</sup></xref>, lo cual es evidente, la peculiaridad del trasplante hep&#x000e1;tico permite la substituci&#x000f3;n temporal de anticalcineur&#x000ed;nicos por GC con relativa seguridad<xref rid="bib0570" ref-type="bibr"><sup>51</sup></xref>.</p></sec><sec id="sec0035"><title>Anticalcineur&#x000ed;nicos</title><p id="par0070">Ciclosporina o tacrolimus son potentes inhibidores de la actividad fosfatasa de la calcineurina linfocitaria y se consideran los medicamentos base en la inmunosupresi&#x000f3;n en el trasplante hep&#x000e1;tico<xref rid="bib0495" ref-type="bibr"><sup>36</sup></xref>. Actualmente se suelen utilizar conjuntamente con MMF o everolimus con objeto de mantener unos niveles plasm&#x000e1;ticos m&#x000e1;s bajos y evitar sus efectos indeseables<xref rid="bib0485" ref-type="bibr">34</xref>, <xref rid="bib0490" ref-type="bibr">35</xref>. La ciclosporina A se une a ciclofilina (receptor intracelular) y forma un complejo activo que inhibe la actividad fosfatasa de la calcineurina. La calcineurina defosforila el componente citoplasm&#x000e1;tico del factor nuclear del linfocito T activado (NFATc), de forma que puede ir al n&#x000fa;cleo y activar los genes involucrados en la s&#x000ed;ntesis de IL-2. IFN-&#x003b3;, IL-4, TNF-&#x003b2;<xref rid="bib0545" ref-type="bibr"><sup>46</sup></xref>. De esta forma, ciclosporina A, al inhibir la calcineurina, inhibe la proliferaci&#x000f3;n de c&#x000e9;lulas T evitando la expansi&#x000f3;n clonal de las c&#x000e9;lulas T cooperadoras y citot&#x000f3;xicas<xref rid="bib0575" ref-type="bibr"><sup>52</sup></xref>. Tacrolimus act&#x000fa;a de forma similar, pero se une a una inmunofilina espec&#x000ed;fica (FKBP) para bloquear la actividad fosfatasa de la calcineurina e inhibir as&#x000ed; la transcripci&#x000f3;n de los genes involucrados en la s&#x000ed;ntesis de IL-2. Su efecto neto sobre covid-19 y particularmente sobre el SARS-CoV-2 se desconoce. Sin embargo, existen datos que indicar&#x000ed;an un efecto antiviral directo de los anticalcineur&#x000ed;nicos. Hace ya algunos a&#x000f1;os se puso en evidencia que la sobreexpresi&#x000f3;n de prote&#x000ed;nas no estructurales de CoV (Nsp1) y la infecci&#x000f3;n con SARS-CoV vivo produjo un incremento muy significativo de la se&#x000f1;al a trav&#x000e9;s de la v&#x000ed;a calcineurina/NFAT y un incremento de la IL-2, compatible con la inmunopatog&#x000e9;nesis y disregulaci&#x000f3;n tard&#x000ed;a de las citoquinas observada en pacientes con SARS grave. Contrariamente, la inhibici&#x000f3;n de las ciclofilinas con ciclosporina A bloque&#x000f3; la replicaci&#x000f3;n de todos los g&#x000e9;neros de coronavirus, incluyendo SARS-CoV, human CoV-229E, etc.<xref rid="bib0575" ref-type="bibr"><sup>52</sup></xref>. Este efecto antiviral de los anticalcineur&#x000ed;nicos, principalmente de la ciclosporina A, ya se hab&#x000ed;a sugerido en el caso de otros virus como el virus de la hepatitis C (VHC)<xref rid="bib0580" ref-type="bibr"><sup>53</sup></xref>. Sin embargo, el balance entre su efecto antiviral y su efecto inmunosupresor no permite, en la mayor&#x000ed;a de los casos, observar un efecto neto antiviral. La informaci&#x000f3;n de la que se dispone en estos momentos no permite afirmar que los anticalcineur&#x000ed;nicos tengan un efecto significativo (positivo o negativo) sobre covid-19.</p><p id="par0075">Si efectuamos una divisi&#x000f3;n simple de los pacientes con covid-19, los podemos clasificar en dos: 1) leves, que incluir&#x000ed;a aquellos asintom&#x000e1;ticos o con s&#x000ed;ntomas como fiebre, tos seca, cansancio, etc., pero sin insuficiencia respiratoria; 2) pacientes con neumon&#x000ed;a e insuficiencia respiratoria. Es evidente que se trata de una clasificaci&#x000f3;n muy simple y que adem&#x000e1;s no tiene en cuenta factores pron&#x000f3;sticos como la linfopenia, LDH, etc.<xref rid="bib0560" ref-type="bibr"><sup>49</sup></xref>, pero puede servir para una decisi&#x000f3;n inicial de tratamiento y de ajuste de los anticalcineur&#x000ed;nicos. En los pacientes leves, la recomendaci&#x000f3;n es no modificar los anticalcineur&#x000ed;nicos, a no ser que se utilicen antivirales como ritonavir-lopinavir con una elevada interferencia, particularmente con tacrolimus<xref rid="bib0585" ref-type="bibr"><sup>54</sup></xref>. En este caso, la dosificaci&#x000f3;n de tacrolimus puede ser de 0,5&#x000a0;mg cada 3-5&#x000a0;d&#x000ed;as. Evidentemente ello requiere un control intensivo de los niveles. Deben valorarse igualmente las interacciones con otros tratamientos (azitromicina, hidroxicloroquina, etc.) que, aunque no obligan a una disminuci&#x000f3;n inicial de las dosis, requieren un control de los niveles de los anticalcineur&#x000ed;nicos. En el caso de los pacientes graves es mejor disminuir o retirar los anticalcineur&#x000ed;nicos, pues evitaremos sus efectos indeseables, las interacciones con otros f&#x000e1;rmacos (en ocasiones m&#x000fa;ltiples) y los ascensos y descensos incontrolados de los niveles (muy dif&#x000ed;ciles de estabilizar en estas situaciones).</p></sec><sec id="sec0040"><title>Micofenolato mofetilo</title><p id="par0080">El MMF es un prof&#x000e1;rmaco que se convierte en &#x000e1;cido micofen&#x000f3;lico (MPA) en el organismo. El metabolismo del MPA implica principalmente la glucuronidaci&#x000f3;n por la enzima uridina 5&#x02019;-difosfato-glucuronosiltransferasa<xref rid="bib0500" ref-type="bibr"><sup>37</sup></xref>. El MPA tiene recirculaci&#x000f3;n entero-hep&#x000e1;tica, lo que alarga su vida media. MPA es un inhibidor reversible y no competitivo de la inosina-5&#x02019;-monofostato deshidrogenasa (IMPDH). Inhibe la proliferaci&#x000f3;n de los linfocitos T y B y la producci&#x000f3;n de inmunoglobulinas mediante la depleci&#x000f3;n del <italic>pool</italic> de guanosina y desoxiguanosina en los linfocitos<xref rid="bib0500" ref-type="bibr">37</xref>, <xref rid="bib0585" ref-type="bibr">54</xref>. Adem&#x000e1;s de esta potente acci&#x000f3;n inmunosupresora, y por tanto facilitadora de infecciones, MPA tiene una amplia actividad <italic>in vitro</italic> y/o en modelos animales frente a diferentes virus, entre los que se incluyen virus del Nilo occidental<xref rid="bib0590" ref-type="bibr"><sup>55</sup></xref>, de la encefalitis japonesa<xref rid="bib0595" ref-type="bibr"><sup>56</sup></xref>, fiebre amarilla y dengue<xref rid="bib0600" ref-type="bibr"><sup>57</sup></xref>, y Chikungunya<xref rid="bib0605" ref-type="bibr"><sup>58</sup></xref>. MPA es tambi&#x000e9;n capaz de inhibir <italic>in vitro</italic> e <italic>in vivo</italic> la replicaci&#x000f3;n del VHC mediante el incremento de la expresi&#x000f3;n g&#x000e9;nica del interfer&#x000f3;n y mediante la depleci&#x000f3;n de guanosina<xref rid="bib0610" ref-type="bibr"><sup>59</sup></xref>. En relaci&#x000f3;n con los coronavirus, MPA no fue efectivo contra el SARS-CoV en un modelo animal, pero s&#x000ed; contra MERS-CoV<xref rid="bib0615" ref-type="bibr"><sup>60</sup></xref>.</p><p id="par0085">A pesar de estos efectos antivirales <italic>in vitro</italic> y en modelos animales, la realidad en la pr&#x000e1;ctica cl&#x000ed;nica del trasplante es muy diferente, en la que predomina claramente el efecto inmunosupresor tal y como se ha visto con el VHC y el citomegalovirus. Por tanto, en nuestra opini&#x000f3;n, el MMF se debe retirar si un paciente trasplantado hep&#x000e1;tico presenta infecci&#x000f3;n por SARS-CoV-2 en cualquier fase o gravedad de la enfermedad. Con independencia de su efecto inmunosupresor descrito, puede producir leucopenia, linfopenia, trombocitopenia y aplasia medular, complicaciones que pueden dificultar enormemente la resoluci&#x000f3;n de la infecci&#x000f3;n o poner en riesgo la vida del paciente.</p></sec><sec id="sec0045"><title>Inhibidores de la m-Tor: sirolimus/everolimus</title><p id="par0090">Sirolimus es un macr&#x000f3;lido, proveniente del actinomiceto <italic>Streptomyces hygroscopicus</italic> descubierto en la Isla de Pascua (Rapa Nui) entre diciembre de 1964 y febrero de 1965 por la <italic>Canadian Medical Research Expedition</italic>
<xref rid="bib0620" ref-type="bibr"><sup>61</sup></xref>. Es metabolizado por el citocromo p450 3A4 requiriendo ajuste de niveles plasm&#x000e1;ticos. El 90% de sus metabolitos se eliminan por las heces. Para actuar, los inhibidores de mTOR precisan formar un complejo con una inmunofilina. Al igual que tacrolimus, se unen a FKBP-12, pero a diferencia de este, no inhiben la calcineurina sino el <italic>mammalian target of rapamycin,</italic> provocando el bloqueo de la se&#x000f1;al desde el receptor de IL-2 inhibiendo la proliferaci&#x000f3;n de c&#x000e9;lulas T y B<xref rid="bib0500" ref-type="bibr"><sup>37</sup></xref>. El everolimus es un derivado del sirolimus con una semivida de eliminaci&#x000f3;n m&#x000e1;s corta y mayor biodisponibilidad oral.</p><p id="par0095">Los inhibidores de mTOR presentan, adem&#x000e1;s de su efecto inmunodepresor, antiproliferativo, etc., propiedades antivirales, bien demostradas en pacientes trasplantados en cuanto a la prevenci&#x000f3;n y/o tratamiento de infecciones por citomegalovirus o virus BK<xref rid="bib0625" ref-type="bibr"><sup>62</sup></xref>. Si bien se ha sugerido que a trav&#x000e9;s de las v&#x000ed;as asociadas a los complejos m-Tor 1 y 2 junto con la activaci&#x000f3;n de la prote&#x000ed;na quinasa (AMPK) podr&#x000ed;a tener un efecto antiviral frente a los coronavirus, no existe evidencia cl&#x000ed;nica. Solo un estudio en pacientes con neumon&#x000ed;a e insuficiencia respiratoria por virus influenza hall&#x000f3; una menor duraci&#x000f3;n del cuadro y menos incidencia de fallo multiorg&#x000e1;nico en los pacientes que recibieron rapamicina<xref rid="bib0630" ref-type="bibr"><sup>63</sup></xref>. No se dispone de evidencia cl&#x000ed;nica para hacer recomendaciones sobre su utilizaci&#x000f3;n en la infecci&#x000f3;n covid-19. Deben valorarse las interacciones farmacol&#x000f3;gicas con otros medicamentos y la posibilidad de leucopenia y linfopenia asociadas.</p></sec></sec><sec id="sec0050"><title>Propuesta de actuaci&#x000f3;n en pacientes trasplantados hep&#x000e1;ticos y covid-19</title><p id="par0100">Seguramente cada uno de los m&#x000e9;dicos que llevan pacientes trasplantados hep&#x000e1;ticos podemos formular una propuesta. La siguiente propuesta solo pretende dar unas l&#x000ed;neas generales de actuaci&#x000f3;n que requerir&#x000e1;n su adaptaci&#x000f3;n a los pacientes. No es lo mismo un trasplantado hep&#x000e1;tico de hace un a&#x000f1;o que otro de hace 10, ni uno con muchas comorbilidades que otro sin, y as&#x000ed; muchas situaciones que obligan a adaptar la inmunosupresi&#x000f3;n a las caracter&#x000ed;sticas de nuestros pacientes. Tal y como hemos mencionado, la propuesta parte de una clasificaci&#x000f3;n muy sencilla pero que permite instaurar el cambio del tratamiento inmunosupresor antes de que se produzcan complicaciones asociadas al mismo (<xref rid="fig0005" ref-type="fig">fig. 1</xref>
).<list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>1.</label><p id="par0105">
<italic>Trasplantados hep&#x000e1;ticos con infecci&#x000f3;n covid-19 asintom&#x000e1;tica o leve</italic> (tos seca, odinofagia, anosmia, fiebre, cansancio y en ocasiones diarrea):</p></list-item><list-item id="lsti0010"><label>a)</label><p id="par0110">Suspender/reducir MMF o everolimus si son parte del tratamiento siempre que sea posible, substituy&#x000e9;ndolos por dosis bajas de prednisona.</p></list-item><list-item id="lsti0015"><label>b)</label><p id="par0115">Vigilar exhaustivamente las interacciones farmacol&#x000f3;gicas, sobre todo en aquellos pacientes con anticalcineur&#x000ed;nicos que reciban antivirales https://www.hiv-druginteractions.org/checker</p></list-item></list>
<fig id="fig0005"><label>Figura 1</label><caption><p>Propuesta de inmunosupresi&#x000f3;n en trasplante hep&#x000e1;tico en la era covid-19. F&#x000e1;rmacos en el tratamiento de covid-19 que deben tenerse especialmente en cuenta por interacciones con anticalcineur&#x000ed;nicos: lopinavir/ritonavir, azitromicina.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="par0120">
<list list-type="simple" id="lis0010"><list-item id="lsti0020"><label>2.</label><p id="par0125">Trasplantados hep&#x000e1;ticos con infecci&#x000f3;n grave (neumon&#x000ed;a en cualquiera de sus fases):</p></list-item><list-item id="lsti0025"><label>a)</label><p id="par0130">Suspender MMF o everolimus.</p></list-item><list-item id="lsti0030"><label>b)</label><p id="par0135">Reducir o suspender anticalcineur&#x000ed;nicos y sustituir por corticoides.</p></list-item><list-item id="lsti0035"><label>c)</label><p id="par0140">Tener en cuenta si el paciente ha recibido inmunomoduladores (tipo inhibidores receptor IL-6) al decidir la dosis de corticoides.</p></list-item><list-item id="lsti0040"><label>d)</label><p id="par0145">Vigilar exhaustivamente las interacciones farmacol&#x000f3;gicas, sobre todo en aquellos pacientes que reciban antivirales https://www.hiv-druginteractions.org/checker</p></list-item></list>
</p></sec><sec id="sec0055"><title>Financiaci&#x000f3;n</title><p id="par0150">La presente investigaci&#x000f3;n no ha recibido ayudas espec&#x000ed;ficas provenientes de agencias del sector p&#x000fa;blico, sector comercial o entidades sin &#x000e1;nimo de lucro.</p></sec><sec id="sec0060"><title>Autor&#x000ed;a</title><p id="par0155">Todos los autores han hecho contribuciones sustanciales en cada uno de los siguientes aspectos: (1) la concepci&#x000f3;n y el dise&#x000f1;o de la revisi&#x000f3;n, o la adquisici&#x000f3;n de datos, o el an&#x000e1;lisis y la interpretaci&#x000f3;n de los datos, (2) el borrador del art&#x000ed;culo o la revisi&#x000f3;n cr&#x000ed;tica del contenido intelectual, (3) la aprobaci&#x000f3;n definitiva de la versi&#x000f3;n que se presenta.</p></sec><sec id="sec0065"><title>Conflicto de intereses</title><p id="par0160">Los autores declaran no tener ning&#x000fa;n conflicto de intereses.</p></sec></body><back><ref-list id="bibl0005"><title>Bibliograf&#x000ed;a</title><ref id="bib0320"><label>1</label><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in&#x000a0;vitro</article-title><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="bib0325"><label>2</label><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name><surname>De Wit</surname><given-names>E.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Cronin</surname><given-names>J.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Okumura</surname><given-names>A.</given-names></name><name><surname>Thomas</surname><given-names>T.</given-names></name></person-group><article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title><source>Proc Natl Acad Sci U S A.</source><volume>117</volume><year>2020</year><fpage>6771</fpage><lpage>6776</lpage><pub-id pub-id-type="doi">10.1073/pnas.1922083117</pub-id><pub-id pub-id-type="pmid">32054787</pub-id></element-citation></ref><ref id="bib0330"><label>3</label><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>M.L.</given-names></name><name><surname>DeBolt</surname><given-names>C.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name><name><surname>Lofy</surname><given-names>K.H.</given-names></name><name><surname>Wiesman</surname><given-names>J.</given-names></name><name><surname>Bruce</surname><given-names>H.</given-names></name></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N Engl J Med.</source><volume>382</volume><year>2020</year><fpage>929</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001191</pub-id><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="bib0335"><label>4</label><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Leist</surname><given-names>S.R.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><name><surname>Won</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>A.J.</given-names></name></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat Commun.</source><volume>11</volume><year>2020</year><fpage>222</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13940-6</pub-id><pub-id pub-id-type="pmid">31924756</pub-id></element-citation></ref><ref id="bib0340"><label>5</label><element-citation publication-type="journal" id="sbref0340"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.A.</given-names></name></person-group><article-title>trial of lopinavir&#x02013;ritonavir in adults hospitalized with severe Covid-19</article-title><source>N Engl J Med.</source><volume>382</volume><year>2020</year><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><pub-id pub-id-type="pmid">32187464</pub-id></element-citation></ref><ref id="bib0345"><label>6</label><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title><source>Biosci Trends.</source><volume>14</volume><year>2020</year><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.5582/bst.2020.01047</pub-id><pub-id pub-id-type="pmid">32074550</pub-id></element-citation></ref><ref id="bib0350"><label>7</label><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</article-title><source>Nat Rev Drug Discov.</source><volume>19</volume><year>2020</year><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id><pub-id pub-id-type="pmid">32127666</pub-id></element-citation></ref><ref id="bib0355"><label>8</label><element-citation publication-type="journal" id="sbref0355"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Discovering drugs to treat coronavirus disease 2019 (COVID-19)</article-title><source>Drug Discoveries Ther.</source><volume>14</volume><year>2020</year><fpage>58</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.5582/ddt.2020.01012</pub-id></element-citation></ref><ref id="bib0360"><label>9</label><element-citation publication-type="journal" id="sbref0360"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P.</given-names></name><name><surname>Lagier</surname><given-names>J.-C.</given-names></name><name><surname>Parola</surname><given-names>P.</given-names></name><name><surname>Hoang</surname><given-names>V.T.</given-names></name><name><surname>Meddeb</surname><given-names>L.</given-names></name><name><surname>Mailhe</surname><given-names>M.</given-names></name></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int J Antimicrob Agents.</source><year>2020</year><fpage>105949</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id><pub-id pub-id-type="pmid">32205204</pub-id></element-citation></ref><ref id="bib0365"><label>10</label><element-citation publication-type="journal" id="sbref0365"><person-group person-group-type="author"><name><surname>Shanmugaraj</surname><given-names>B.</given-names></name><name><surname>Siriwattananon</surname><given-names>K.</given-names></name><name><surname>Wangkanont</surname><given-names>K.</given-names></name><name><surname>Phoolcharoen</surname><given-names>W.</given-names></name></person-group><article-title>Perspectives on Monoclonal Antibody Therapy as Potential Therapeutic Intervention for Coronavirus disease-19 (COVID-19)</article-title><source>Asian Pac J Allergy Immunol.</source><volume>38</volume><year>2020</year><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.12932/AP-200220-0773</pub-id><pub-id pub-id-type="pmid">32134278</pub-id></element-citation></ref><ref id="bib0370"><label>11</label><element-citation publication-type="journal" id="sbref0370"><person-group person-group-type="author"><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Netland</surname><given-names>J.</given-names></name></person-group><article-title>Coronaviruses post-SARS: update on replication and pathogenesis</article-title><source>Nat Rev Microbiol.</source><volume>7</volume><year>2009</year><fpage>439</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2147</pub-id><pub-id pub-id-type="pmid">19430490</pub-id></element-citation></ref><ref id="bib0375"><label>12</label><element-citation publication-type="journal" id="sbref0375"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Coronavirus diversity, phylogeny and interspecies jumping</article-title><source>Exp Biol Med (Maywood).</source><volume>234</volume><year>2009</year><fpage>1117</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.3181/0903-MR-94</pub-id><pub-id pub-id-type="pmid">19546349</pub-id></element-citation></ref><ref id="bib0380"><label>13</label><element-citation publication-type="journal" id="sbref0380"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Geng</surname><given-names>M.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name></person-group><article-title>Molecular immune pathogenesis and diagnosis of COVID-19</article-title><source>J Pharm Anal.</source><volume>10</volume><year>2020</year><fpage>102</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.001</pub-id><pub-id pub-id-type="pmid">32282863</pub-id></element-citation></ref><ref id="bib0385"><label>14</label><element-citation publication-type="journal" id="sbref0385"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.J.</given-names></name><name><surname>Ni</surname><given-names>Z.Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.H.</given-names></name><name><surname>Ou</surname><given-names>C.Q.</given-names></name><name><surname>He</surname><given-names>J.X.</given-names></name></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Engl J Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id></element-citation></ref><ref id="bib0390"><label>15</label><element-citation publication-type="journal" id="sbref0390"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Stohr</surname><given-names>K.</given-names></name></person-group><article-title>The severe acute respiratory syndrome</article-title><source>N Engl J Med.</source><volume>349</volume><year>2003</year><fpage>2431</fpage><lpage>2441</lpage><pub-id pub-id-type="doi">10.1056/NEJMra032498</pub-id><pub-id pub-id-type="pmid">14681510</pub-id></element-citation></ref><ref id="bib0395"><label>16</label><element-citation publication-type="journal" id="sbref0395"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.F.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Field</surname><given-names>H.</given-names></name><name><surname>Daszak</surname><given-names>P.</given-names></name></person-group><article-title>Review of bats and SARS</article-title><source>Emerg Infect Dis.</source><volume>12</volume><year>2006</year><fpage>1834</fpage><lpage>1840</lpage><pub-id pub-id-type="doi">10.3201/eid1212.060401</pub-id><pub-id pub-id-type="pmid">17326933</pub-id></element-citation></ref><ref id="bib0400"><label>17</label><element-citation publication-type="journal" id="sbref0400"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>J.F.</given-names></name><name><surname>Gloza-Rausch</surname><given-names>F.</given-names></name><name><surname>Glende</surname><given-names>J.</given-names></name><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Goettsche</surname><given-names>M.</given-names></name></person-group><article-title>Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences</article-title><source>J Virol.</source><volume>84</volume><year>2010</year><fpage>11336</fpage><lpage>11349</lpage><pub-id pub-id-type="doi">10.1128/JVI.00650-10</pub-id><pub-id pub-id-type="pmid">20686038</pub-id></element-citation></ref><ref id="bib0405"><label>18</label><element-citation publication-type="journal" id="sbref0405"><person-group person-group-type="author"><name><surname>Lessler</surname><given-names>J.</given-names></name><name><surname>Reich</surname><given-names>N.G.</given-names></name><name><surname>Brookmeyer</surname><given-names>R.</given-names></name><name><surname>Perl</surname><given-names>T.M.</given-names></name><name><surname>Nelson</surname><given-names>K.E.</given-names></name><name><surname>Cummings</surname><given-names>D.A.</given-names></name></person-group><article-title>Incubation periods of acute respiratory viral infections: a systematic review</article-title><source>Lancet Infect Dis.</source><volume>9</volume><year>2009</year><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(09)70069-6</pub-id><pub-id pub-id-type="pmid">19393959</pub-id></element-citation></ref><ref id="bib0410"><label>19</label><element-citation publication-type="journal" id="sbref0410"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kruger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id></element-citation></ref><ref id="bib0415"><label>20</label><element-citation publication-type="journal" id="sbref0415"><person-group person-group-type="author"><name><surname>Felsenstein</surname><given-names>S.</given-names></name><name><surname>Herbert</surname><given-names>J.A.</given-names></name><name><surname>McNamara</surname><given-names>P.S.</given-names></name><name><surname>Hedrich</surname><given-names>C.M.</given-names></name></person-group><article-title>COVID-19: Immunology and treatment options</article-title><source>Clin Immunol.</source><volume>215</volume><year>2020</year><fpage>108448</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2020.108448</pub-id><pub-id pub-id-type="pmid">32353634</pub-id></element-citation></ref><ref id="bib0420"><label>21</label><element-citation publication-type="journal" id="sbref0420"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P.</given-names></name><name><surname>McAuley</surname><given-names>D.F.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><name><surname>Tattersall</surname><given-names>R.S.</given-names></name><name><surname>Manson</surname><given-names>J.J.</given-names></name></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet.</source><volume>395</volume><year>2020</year><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="bib0425"><label>22</label><element-citation publication-type="journal" id="sbref0425"><person-group person-group-type="author"><name><surname>Mahallawi</surname><given-names>W.H.</given-names></name><name><surname>Khabour</surname><given-names>O.F.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Makhdoum</surname><given-names>H.M.</given-names></name><name><surname>Suliman</surname><given-names>B.A.</given-names></name></person-group><article-title>MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile</article-title><source>Cytokine.</source><volume>104</volume><year>2018</year><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2018.01.025</pub-id><pub-id pub-id-type="pmid">29414327</pub-id></element-citation></ref><ref id="bib0430"><label>23</label><element-citation publication-type="journal" id="sbref0430"><person-group person-group-type="author"><name><surname>Prompetchara</surname><given-names>E.</given-names></name><name><surname>Ketloy</surname><given-names>C.</given-names></name><name><surname>Palaga</surname><given-names>T.</given-names></name></person-group><article-title>Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic</article-title><source>Asian Pac J Allergy Immunol.</source><volume>38</volume><year>2020</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.12932/AP-200220-0772</pub-id><pub-id pub-id-type="pmid">32105090</pub-id></element-citation></ref><ref id="bib0435"><label>24</label><element-citation publication-type="journal" id="sbref0435"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>C.K.</given-names></name><name><surname>Lam</surname><given-names>C.W.</given-names></name><name><surname>Wu</surname><given-names>A.K.</given-names></name><name><surname>Ip</surname><given-names>W.K.</given-names></name><name><surname>Lee</surname><given-names>N.L.</given-names></name><name><surname>Chan</surname><given-names>I.H.</given-names></name></person-group><article-title>Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome</article-title><source>Clin Exp Immunol.</source><volume>136</volume><year>2004</year><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2004.02415.x</pub-id><pub-id pub-id-type="pmid">15030519</pub-id></element-citation></ref><ref id="bib0440"><label>25</label><element-citation publication-type="journal" id="sbref0440"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>M.Z.</given-names></name><name><surname>Poh</surname><given-names>C.M.</given-names></name><name><surname>R&#x000e9;nia</surname><given-names>L.</given-names></name><name><surname>MacAry</surname><given-names>P.A.</given-names></name><name><surname>Ng</surname><given-names>L.F.P.</given-names></name></person-group><article-title>The trinity of COVID-19: immunity, inflammation and intervention</article-title><source>Nat Rev Immunol.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41577-020-0311-8</pub-id></element-citation></ref><ref id="bib0445"><label>26</label><element-citation publication-type="journal" id="sbref0445"><person-group person-group-type="author"><name><surname>Shokri</surname><given-names>S.</given-names></name><name><surname>Mahmoudvand</surname><given-names>S.</given-names></name><name><surname>Taherkhani</surname><given-names>R.</given-names></name><name><surname>Farshadpour</surname><given-names>F.</given-names></name></person-group><article-title>Modulation of the immune response by Middle East respiratory syndrome coronavirus</article-title><source>J Cell Physiol.</source><volume>234</volume><year>2019</year><fpage>2143</fpage><lpage>2151</lpage><pub-id pub-id-type="doi">10.1002/jcp.27155</pub-id><pub-id pub-id-type="pmid">30146782</pub-id></element-citation></ref><ref id="bib0450"><label>27</label><element-citation publication-type="journal" id="sbref0450"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>H.S.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>Jeong</surname><given-names>I.</given-names></name><name><surname>Joh</surname><given-names>J.S.</given-names></name></person-group><article-title>Immune responses to Middle East respiratory syndrome coronavirus during the acute and convalescent phases of human infection</article-title><source>Clin Infect Dis.</source><volume>68</volume><year>2019</year><fpage>984</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy595</pub-id><pub-id pub-id-type="pmid">30060038</pub-id></element-citation></ref><ref id="bib0455"><label>28</label><element-citation publication-type="journal" id="sbref0455"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Mangalam</surname><given-names>A.K.</given-names></name><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>Meyerholz</surname><given-names>D.K.</given-names></name></person-group><article-title>Airway Memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses</article-title><source>Immunity.</source><volume>44</volume><year>2016</year><fpage>1379</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.006</pub-id><pub-id pub-id-type="pmid">27287409</pub-id></element-citation></ref><ref id="bib0460"><label>29</label><element-citation publication-type="journal" id="sbref0460"><person-group person-group-type="author"><name><surname>Kikkert</surname><given-names>M.</given-names></name></person-group><article-title>Innate immune evasion by human respiratory RNA viruses</article-title><source>J Innate Immun.</source><volume>12</volume><year>2020</year><fpage>4</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1159/000503030</pub-id><pub-id pub-id-type="pmid">31610541</pub-id></element-citation></ref><ref id="bib0465"><label>30</label><element-citation publication-type="journal" id="sbref0465"><person-group person-group-type="author"><name><surname>De Wit</surname><given-names>E.</given-names></name><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>Munster</surname><given-names>V.J.</given-names></name></person-group><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nat Rev Microbiol.</source><volume>14</volume><year>2016</year><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="bib0470"><label>31</label><element-citation publication-type="journal" id="sbref0470"><person-group person-group-type="author"><name><surname>Hermann-Kleiter</surname><given-names>N.</given-names></name><name><surname>Baier</surname><given-names>G.</given-names></name></person-group><article-title>NFAT pulls the strings during CD4+ T helper cell effector functions</article-title><source>Blood.</source><volume>115</volume><year>2010</year><fpage>2989</fpage><lpage>2997</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-233585</pub-id><pub-id pub-id-type="pmid">20103781</pub-id></element-citation></ref><ref id="bib0475"><label>32</label><element-citation publication-type="journal" id="sbref0475"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.K.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>T cell responses to whole SARS coronavirus in humans</article-title><source>J Immunol.</source><volume>181</volume><year>2008</year><fpage>5490</fpage><lpage>5500</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.8.5490</pub-id><pub-id pub-id-type="pmid">18832706</pub-id></element-citation></ref><ref id="bib0480"><label>33</label><element-citation publication-type="journal" id="sbref0480"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Fontanet</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>P.H.</given-names></name><name><surname>Zhan</surname><given-names>L.</given-names></name><name><surname>Xin</surname><given-names>Z.T.</given-names></name><name><surname>Baril</surname><given-names>L.</given-names></name></person-group><article-title>Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome</article-title><source>J Infect Dis.</source><volume>193</volume><year>2006</year><fpage>792</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1086/500469</pub-id><pub-id pub-id-type="pmid">16479513</pub-id></element-citation></ref><ref id="bib0485"><label>34</label><element-citation publication-type="journal" id="sbref0485"><person-group person-group-type="author"><name><surname>Castells</surname><given-names>L.</given-names></name><name><surname>Baliellas</surname><given-names>C.</given-names></name><name><surname>Bilbao</surname><given-names>I.</given-names></name><name><surname>Cantarell</surname><given-names>V.</given-names></name><name><surname>Cruzado</surname><given-names>J.M.</given-names></name><name><surname>Esforzado</surname><given-names>N.</given-names></name></person-group><article-title>Detecci&#x000f3;n precoz, prevenci&#x000f3;n y manejo de la insuficiencia renal en el trasplante hep&#x000e1;tico</article-title><source>Gastroenterol Hepatol.</source><volume>37</volume><year>2014</year><fpage>480</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/j.gastrohep.2013.11.006</pub-id><pub-id pub-id-type="pmid">25060591</pub-id></element-citation></ref><ref id="bib0490"><label>35</label><element-citation publication-type="journal" id="sbref0490"><person-group person-group-type="author"><name><surname>Serrano</surname><given-names>M.T.</given-names></name><name><surname>Parra</surname><given-names>E.</given-names></name><name><surname>Lorente</surname><given-names>S.</given-names></name></person-group><article-title>Inmunosupresi&#x000f3;n en el trasplante hep&#x000e1;tico: pautas renoprotectoras</article-title><source>Gastroenterol Hepatol.</source><volume>34</volume><year>2011</year><fpage>422</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.gastrohep.2010.12.009</pub-id><pub-id pub-id-type="pmid">21458889</pub-id></element-citation></ref><ref id="bib0495"><label>36</label><element-citation publication-type="journal" id="sbref0495"><person-group person-group-type="author"><name><surname>Moini</surname><given-names>M.</given-names></name><name><surname>Schilsky</surname><given-names>M.L.</given-names></name><name><surname>Tichy</surname><given-names>E.M.</given-names></name></person-group><article-title>Review on immunosuppression in liver transplantation</article-title><source>World J Hepatol.</source><volume>7</volume><year>2015</year><fpage>1355</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.4254/wjh.v7.i10.1355</pub-id><pub-id pub-id-type="pmid">26052381</pub-id></element-citation></ref><ref id="bib0500"><label>37</label><element-citation publication-type="journal" id="sbref0500"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>A.L.</given-names></name><name><surname>Watson</surname><given-names>C.J.E.</given-names></name><name><surname>Bradley</surname><given-names>J.A.</given-names></name></person-group><article-title>Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy</article-title><source>Crit Rev Oncol Hematol.</source><volume>56</volume><year>2005</year><fpage>23</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2005.03.012</pub-id><pub-id pub-id-type="pmid">16039869</pub-id></element-citation></ref><ref id="bib0505"><label>38</label><element-citation publication-type="journal" id="sbref0505"><person-group person-group-type="author"><name><surname>Bhoori</surname><given-names>S.</given-names></name><name><surname>Rossi</surname><given-names>R.E.</given-names></name><name><surname>Citterio</surname><given-names>D.</given-names></name><name><surname>Mazzaferro</surname><given-names>V.</given-names></name></person-group><article-title>COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy</article-title><source>Lancet Gastroenterol Hepatol.</source><volume>5</volume><year>2020</year><fpage>532</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(20)30116-3</pub-id><pub-id pub-id-type="pmid">32278366</pub-id></element-citation></ref><ref id="bib0510"><label>39</label><element-citation publication-type="journal" id="sbref0510"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>M.R.</given-names></name><name><surname>Mohan</surname><given-names>S.</given-names></name><name><surname>Cohen</surname><given-names>D.J.</given-names></name><name><surname>Husain</surname><given-names>S.A.</given-names></name><name><surname>Dube</surname><given-names>G.K.</given-names></name><name><surname>Ratner</surname><given-names>L.E.</given-names></name></person-group><article-title>COVID-19 in solid organ transplant recipients: initial report from the US Epicenter</article-title><source>Am J Transplant.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/ajt.15941</pub-id></element-citation></ref><ref id="bib0515"><label>40</label><mixed-citation publication-type="other" id="oref0200">Sociedad Espa&#x000f1;ola de Trasplante Hep&#x000e1;tico [consultado 3 May 2020]. Disponible en <ext-link ext-link-type="uri" xlink:href="https://www.sethepatico.org/login.php?url=%2Fcasoscovid19.php" id="intr0005">https://www.sethepatico.org/login.php?url=%2Fcasoscovid19.php</ext-link></mixed-citation></ref><ref id="bib0520"><label>41</label><element-citation publication-type="journal" id="sbref0520"><person-group person-group-type="author"><name><surname>D&#x02019;Antiga</surname><given-names>L.</given-names></name></person-group><article-title>Coronaviruses and immunosuppressed patients. The facts during the third epidemic</article-title><source>Liver Transpl.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/lt.25756</pub-id></element-citation></ref><ref id="bib0525"><label>42</label><element-citation publication-type="journal" id="sbref0525"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M.</given-names></name></person-group><article-title>Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies</article-title><source>Int J Antimicrob Agents.</source><volume>16</volume><year>2020</year><fpage>105982</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105982</pub-id></element-citation></ref><ref id="bib0530"><label>43</label><element-citation publication-type="journal" id="sbref0530"><person-group person-group-type="author"><name><surname>Jamilloux</surname><given-names>Y.</given-names></name><name><surname>Henry</surname><given-names>T.</given-names></name><name><surname>Belot</surname><given-names>A.</given-names></name><name><surname>Viel</surname><given-names>S.</given-names></name><name><surname>Fauter</surname><given-names>M.</given-names></name><name><surname>El Jammal</surname><given-names>T.</given-names></name></person-group><article-title>Should we stimulate or suppress immune responses in&#x000a0;COVID-19? Cytokine and anti-cytokine interventions</article-title><source>Autoimmun Rev.</source><volume>19</volume><year>2020</year><fpage>102567</fpage><pub-id pub-id-type="doi">10.1016/j.autrev.2020.102567</pub-id><pub-id pub-id-type="pmid">32376392</pub-id></element-citation></ref><ref id="bib0535"><label>44</label><element-citation publication-type="journal" id="sbref0535"><person-group person-group-type="author"><name><surname>Napolitano</surname><given-names>M.</given-names></name><name><surname>Fabbrocini</surname><given-names>G.</given-names></name><name><surname>Patruno</surname><given-names>C.J.</given-names></name></person-group><article-title>Potential role of Janus kinase inhibitors in COVID-19</article-title><source>Am Acad Dermatol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jaad.2020.04.098</pub-id></element-citation></ref><ref id="bib0540"><label>45</label><element-citation publication-type="journal" id="sbref0540"><person-group person-group-type="author"><name><surname>Rovira</surname><given-names>J.</given-names></name><name><surname>Ram&#x000ed;rez-Bajo</surname><given-names>M.J.</given-names></name><name><surname>Banon-Maneus</surname><given-names>E.</given-names></name><name><surname>Lazo-Rodr&#x000ed;guez</surname><given-names>M.</given-names></name><name><surname>Moya-Rull</surname><given-names>D.</given-names></name><name><surname>Hierro-Garcia</surname><given-names>N.</given-names></name></person-group><article-title>Tofacitinib halts progression of graft dysfunction in a rat model of mixed cellular and humoral rejection</article-title><source>Transplantation.</source><volume>102</volume><year>2018</year><fpage>1075</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000002204</pub-id><pub-id pub-id-type="pmid">29620612</pub-id></element-citation></ref><ref id="bib0545"><label>46</label><element-citation publication-type="journal" id="sbref0545"><person-group person-group-type="author"><name><surname>Matthay</surname><given-names>M.A.</given-names></name><name><surname>Zemans</surname><given-names>R.L.</given-names></name><name><surname>Zimmerman</surname><given-names>G.A.</given-names></name><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Beitler</surname><given-names>J.R.</given-names></name><name><surname>Mercat</surname><given-names>A.</given-names></name></person-group><article-title>Acute respiratory distress syndrome</article-title><source>Nat Rev Dis Primers.</source><volume>5</volume><year>2019</year><fpage>18</fpage><pub-id pub-id-type="doi">10.1038/s41572-019-0069-0</pub-id><pub-id pub-id-type="pmid">30872586</pub-id></element-citation></ref><ref id="bib0550"><label>47</label><element-citation publication-type="journal" id="sbref0550"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>R.B.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name></person-group><article-title>On the use of corticosteroids for 2019- nCoV pneumonia</article-title><source>Lancet.</source><volume>395</volume><year>2020</year><fpage>683</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30361-5</pub-id><pub-id pub-id-type="pmid">32122468</pub-id></element-citation></ref><ref id="bib0555"><label>48</label><element-citation publication-type="journal" id="sbref0555"><person-group person-group-type="author"><name><surname>Schulert</surname><given-names>G.S.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Fall</surname><given-names>N.</given-names></name><name><surname>Husami</surname><given-names>A.</given-names></name><name><surname>Kissell</surname><given-names>D.</given-names></name><name><surname>Hanosh</surname><given-names>A.</given-names></name></person-group><article-title>Whole exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza</article-title><source>J Infect Dis.</source><volume>213</volume><year>2016</year><fpage>1180</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv550</pub-id><pub-id pub-id-type="pmid">26597256</pub-id></element-citation></ref><ref id="bib0560"><label>49</label><element-citation publication-type="journal" id="sbref0560"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>C.D.</given-names></name><name><surname>Millar</surname><given-names>J.E.</given-names></name><name><surname>Baillie</surname><given-names>J.K.</given-names></name></person-group><article-title>Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury</article-title><source>Lancet.</source><volume>395</volume><year>2020</year><fpage>473</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30317-2</pub-id><pub-id pub-id-type="pmid">32043983</pub-id></element-citation></ref><ref id="bib0565"><label>50</label><element-citation publication-type="journal" id="sbref0565"><person-group person-group-type="author"><name><surname>Fix</surname><given-names>O.K.</given-names></name><name><surname>Hameed</surname><given-names>B.</given-names></name><name><surname>Fontana</surname><given-names>R.J.</given-names></name><name><surname>Kwok</surname><given-names>R.M.</given-names></name><name><surname>McGuire</surname><given-names>B.M.</given-names></name><name><surname>Mulligan</surname><given-names>D.C.</given-names></name></person-group><article-title>Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement</article-title><source>Hepatology.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/hep.31281</pub-id></element-citation></ref><ref id="bib0570"><label>51</label><element-citation publication-type="journal" id="sbref0570"><person-group person-group-type="author"><name><surname>Ben&#x000ed;tez</surname><given-names>C.</given-names></name><name><surname>Londo&#x000f1;o</surname><given-names>M.C.</given-names></name><name><surname>Miquel</surname><given-names>R.</given-names></name><name><surname>Manzia</surname><given-names>T.M.</given-names></name><name><surname>Abraldes</surname><given-names>J.G.</given-names></name><name><surname>Lozano</surname><given-names>J.J.</given-names></name></person-group><article-title>Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients</article-title><source>Hepatology.</source><volume>58</volume><year>2013</year><fpage>1824</fpage><lpage>1835</lpage><pub-id pub-id-type="doi">10.1002/hep.26426</pub-id><pub-id pub-id-type="pmid">23532679</pub-id></element-citation></ref><ref id="bib0575"><label>52</label><element-citation publication-type="journal" id="sbref0575"><person-group person-group-type="author"><name><surname>Pfefferle</surname><given-names>S.</given-names></name><name><surname>Sch&#x000f6;pf</surname><given-names>J.</given-names></name><name><surname>K&#x000f6;gl</surname><given-names>M.</given-names></name><name><surname>Friedel</surname><given-names>C.C.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name><name><surname>Carbajo-Lozoya</surname><given-names>J.</given-names></name></person-group><article-title>The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors</article-title><source>PLoS Pathog.</source><volume>7</volume><year>2011</year><fpage>e1002331</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002331</pub-id><pub-id pub-id-type="pmid">22046132</pub-id></element-citation></ref><ref id="bib0580"><label>53</label><element-citation publication-type="journal" id="sbref0580"><person-group person-group-type="author"><name><surname>Membreno</surname><given-names>F.E.</given-names></name><name><surname>Espinales</surname><given-names>J.C.</given-names></name><name><surname>Lawitz</surname><given-names>E.J.</given-names></name></person-group><article-title>Cyclophilin inhibitors for&#x000a0;hepatitis&#x000a0;C&#x000a0;therapy</article-title><source>Clin Liver Dis.</source><volume>17</volume><year>2013</year><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2012.09.008</pub-id><pub-id pub-id-type="pmid">23177289</pub-id></element-citation></ref><ref id="bib0585"><label>54</label><element-citation publication-type="journal" id="sbref0585"><person-group person-group-type="author"><name><surname>Badri</surname><given-names>P.S.</given-names></name><name><surname>Parikh</surname><given-names>A.</given-names></name><name><surname>Coakley</surname><given-names>E.P.</given-names></name><name><surname>Ding</surname><given-names>B.</given-names></name><name><surname>Awni</surname><given-names>W.M.</given-names></name><name><surname>Dutta</surname><given-names>S.</given-names></name></person-group><article-title>Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis c infection</article-title><source>Ther Drug Monit.</source><volume>38</volume><year>2016</year><fpage>640</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000315</pub-id><pub-id pub-id-type="pmid">27310199</pub-id></element-citation></ref><ref id="bib0590"><label>55</label><element-citation publication-type="journal" id="sbref0590"><person-group person-group-type="author"><name><surname>Morrey</surname><given-names>J.D.</given-names></name><name><surname>Smee</surname><given-names>D.F.</given-names></name><name><surname>Sidwell</surname><given-names>R.W.</given-names></name><name><surname>Tseng</surname><given-names>C.</given-names></name></person-group><article-title>Identification of active antiviral compounds against a New York Isolate of West Nile Virus</article-title><source>Antiviral Res.</source><volume>55</volume><year>2002</year><fpage>107</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/s0166-3542(02)00013-x</pub-id><pub-id pub-id-type="pmid">12076755</pub-id></element-citation></ref><ref id="bib0595"><label>56</label><element-citation publication-type="journal" id="sbref0595"><person-group person-group-type="author"><name><surname>Sebastian</surname><given-names>L.</given-names></name><name><surname>Madhusudana</surname><given-names>S.N.</given-names></name><name><surname>Ravi</surname><given-names>V.</given-names></name><name><surname>Desai</surname><given-names>A.</given-names></name></person-group><article-title>Mycophenolic acid inhibits replication of Japanese encephalitis virus</article-title><source>Chemotherapy.</source><volume>57</volume><year>2011</year><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1159/000321483</pub-id><pub-id pub-id-type="pmid">21282947</pub-id></element-citation></ref><ref id="bib0600"><label>57</label><element-citation publication-type="journal" id="sbref0600"><person-group person-group-type="author"><name><surname>Leyssen</surname><given-names>P.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>de Clercq</surname><given-names>E.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name></person-group><article-title>The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase</article-title><source>J Virol.</source><volume>79</volume><year>2005</year><fpage>1943</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.3.1943-1947.2005</pub-id><pub-id pub-id-type="pmid">15650220</pub-id></element-citation></ref><ref id="bib0605"><label>58</label><element-citation publication-type="journal" id="sbref0605"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>P.</given-names></name><name><surname>Chu</surname><given-names>J.J.</given-names></name></person-group><article-title>Chikungunya virus: an update on antiviral development and challenges</article-title><source>Drug Discov Today.</source><volume>18</volume><year>2013</year><fpage>969</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2013.05.002</pub-id><pub-id pub-id-type="pmid">23684571</pub-id></element-citation></ref><ref id="bib0610"><label>59</label><element-citation publication-type="journal" id="sbref0610"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q.</given-names></name><name><surname>de Ruiter</surname><given-names>P.E.</given-names></name><name><surname>Metselaar</surname><given-names>H.J.</given-names></name><name><surname>Kwekkeboom</surname><given-names>J.</given-names></name><name><surname>de Jonge</surname><given-names>J.</given-names></name><name><surname>Tilanus</surname><given-names>H.W.</given-names></name></person-group><article-title>Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo</article-title><source>Hepatology.</source><volume>55</volume><year>2012</year><fpage>1673</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1002/hep.25562</pub-id><pub-id pub-id-type="pmid">22213147</pub-id></element-citation></ref><ref id="bib0615"><label>60</label><element-citation publication-type="journal" id="sbref0615"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.P.W.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Kao</surname><given-names>R.Y.T.</given-names></name><name><surname>To</surname><given-names>K.K.W</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>Li</surname><given-names>C.P.Y.</given-names></name></person-group><article-title>Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus</article-title><source>J Infect.</source><volume>67</volume><year>2013</year><fpage>606</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2013.09.029</pub-id><pub-id pub-id-type="pmid">24096239</pub-id></element-citation></ref><ref id="bib0620"><label>61</label><element-citation publication-type="journal" id="sbref0620"><article-title>A long and winding sTORy</article-title><source>Nat Cell Biol.</source><volume>19</volume><year>2017</year><fpage>1131</fpage><pub-id pub-id-type="doi">10.1038/ncb3624</pub-id><pub-id pub-id-type="pmid">28960201</pub-id></element-citation></ref><ref id="bib0625"><label>62</label><element-citation publication-type="journal" id="sbref0625"><person-group person-group-type="author"><name><surname>Bowman</surname><given-names>L.J.</given-names></name><name><surname>Brueckner</surname><given-names>A.J.</given-names></name><name><surname>Doligalski</surname><given-names>C.T.</given-names></name></person-group><article-title>The Role of mTOR Inhibitors in the management of viral infections: a review of current literature</article-title><source>Transplantation.</source><volume>102</volume><issue>2S</issue><year>2018</year><fpage>S50</fpage><lpage>S59</lpage><pub-id pub-id-type="doi">10.1097/TP.0000000000001777</pub-id><pub-id pub-id-type="pmid">29369973</pub-id></element-citation></ref><ref id="bib0630"><label>63</label><element-citation publication-type="journal" id="sbref0630"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.H.</given-names></name><name><surname>Chung</surname><given-names>F.T.</given-names></name><name><surname>Lin</surname><given-names>S.M.</given-names></name><name><surname>Huang</surname><given-names>S.Y.</given-names></name><name><surname>Chou</surname><given-names>C.L.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name></person-group><article-title>Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure</article-title><source>Crit Care Med.</source><volume>42</volume><year>2014</year><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3182a2727d</pub-id><pub-id pub-id-type="pmid">24105455</pub-id></element-citation></ref></ref-list></back></article>